Last reviewed · How we verify
Lu AG09222
At a glance
| Generic name | Lu AG09222 |
|---|---|
| Sponsor | H. Lundbeck A/S |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments (PHASE2)
- A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine (PHASE1)
- A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments (PHASE2)
- A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants (PHASE1)
- A Trial to Learn More About Repeated Monthly Injections of Lu AG09222 in Participants With Allergies to Grass Pollen (PHASE1)
- A Single Dose Study of Lu AG09222 in a Headache Model With Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lu AG09222 CI brief — competitive landscape report
- Lu AG09222 updates RSS · CI watch RSS
- H. Lundbeck A/S portfolio CI